Freedom of Information Request ID
7274
Date of response
April 2022
Q1. In the past 3 months (or the latest 3 months data you have available), how many Metastatic/advanced Breast cancer patients were treated with:
Abemaciclib (Verzenios) + aromatase inhibitor *
Abemaciclib (Verzenios) + Fulvestrant (Faslodex)
Alpelisib (Piqray) + Fulvestrant (Faslodex)
Atezolizumab (Tecentriq)**
Bevacizumab (Avastin)
Eribulin (Halaven)
Everolimus (Afinitor) + Exemestane
Fulvestrant (Faslodex) as a single agent
Gemcitabine + paclitaxel
Herceptin (Trastuzumab) + paclitaxel
Herceptin (Trastuzumab) as a single agent
Lapatinib (Tyverb)
Neratinib (Nerlynx)
Olaparib (Lynparza)
Palbociclib (Ibrance) + aromatase inhibitor*
Palbociclib (Ibrance) + Fulvestrant (Faslodex)
Pertuzumab (Perjeta) + trastuzumab + docetaxel
Ribociclib (Kisqali) + aromatase inhibitor*
Ribociclib (Kisqali) + Fulvestrant (Faslodex)
Talazoparib (Talzenna)
Trastuzumab emtansine (Kadcyla)
Other active systemic anti-cancer therapy **
*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole
**eg. docetaxel, vinorelbine or capecitabine as a single agent
*Please see below.
Q2. For the above patients, how many of these received their first ever dose for each product line?
The Trust regret this data is not collated.
*Medway NHS Foundation Trust regret that we are unable to answer this question. This is because the Trust’s Pharmacy department can provide data on the number of patients that were issued each drug, but their records do not show the indication that each drug was prescribed for. Please see below pharmacy data for the reporting period 01/01/2022 to 31/03/2022 for the BNF Category: Immune System & Malignant Disease (Chapter 8). Please note, that if the drug is not listed, it is because it has not been issued. Where the number is less than five, this has been marked as <5.
FOI Requests
The Freedom of Information Act 2000 provides people with a right of access to a wide range of information held by public authorities, including the NHS.
FOI Disclosure Log
A collection of the most common FOI requests we have received and responded to.